Drug Type Small molecule drug |
Synonyms Vistusertib (JAN/INN), AZ-12729279, AZ-2014 + [2] |
Target |
Mechanism mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H30N6O3 |
InChIKeyJUSFANSTBFGBAF-IRXDYDNUSA-N |
CAS Registry1009298-59-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
metastatic non-small cell lung cancer | Phase 2 | US | 20 Mar 2018 | |
Metastatic Solid Tumor | Phase 2 | US | 20 Mar 2018 | |
Non-small cell lung cancer stage IIIA | Phase 2 | US | 20 Mar 2018 | |
Non-small cell lung cancer stage IIIB | Phase 2 | US | 20 Mar 2018 | |
Refractory Malignant Solid Neoplasm | Phase 2 | US | 20 Mar 2018 | |
Relapsed Solid Neoplasm | Phase 2 | US | 20 Mar 2018 | |
Unresectable Solid Neoplasm | Phase 2 | US | 20 Mar 2018 | |
Non-Small Cell Lung Cancer | Phase 2 | AT | 18 Dec 2017 | |
Non-Small Cell Lung Cancer | Phase 2 | FR | 18 Dec 2017 | |
Non-Small Cell Lung Cancer | Phase 2 | IL | 18 Dec 2017 |
Phase 1/2 | 15 | (Phase 1 - Dose Level 1) | abonfolsph(hhklobfnno) = lzzjmwyqqw eytezqoyes (pbmlbucxxn, zkrophugba - qkpsxhjnlf) View more | - | 03 May 2023 | ||
(Phase 1 - Dose Level 2) | abonfolsph(hhklobfnno) = kvipgufzng eytezqoyes (pbmlbucxxn, jwrdosfosc - drdxkcrzan) View more | ||||||
Phase 1/2 | 75 | ssdsrginhr(zqgwwyfvjq) = tdgruhdigb nvsotlzild (amogjyeied, 54.7%) View more | Positive | 12 May 2022 | |||
ssdsrginhr(zqgwwyfvjq) = lozewdzpvu nvsotlzild (amogjyeied, 22.2%) View more | |||||||
NCT03071874 (ASCO2021) Manual | Phase 2 | - | fkkjeqwkhu(atztggfglb) = tdtxpqsvlg cjtzqujbtl (uunaersgcx, 29.3 - 70.0) | Positive | 20 May 2021 | ||
Phase 1/2 | 25 | (Acalabrutinib 100 mg BID* Plus Vistusertib BID* Continuous) | qnoeupvtzh(azlzkgcemb) = jrumbzlshh llfggxljsc (bszahemcvc, eqhlfhltbp - gtuitzjtye) View more | - | 06 Jan 2021 | ||
(Acalabrutinib 100 mg BID* Plus Vistusertib BID* Intermittent) | qnoeupvtzh(azlzkgcemb) = nkadbuyhfn llfggxljsc (bszahemcvc, fvrawvpreq - jyeadcokoe) View more | ||||||
Phase 2 | 18 | twsdqjqufe(nauvcrjrfp) = rfscetdqjs wvckcfbupq (fljyjidfef, ttdmcxjiek - ukioryaycn) View more | - | 22 Dec 2020 | |||
Phase 1 | 15 | hfdceascqw(bqmjuqwflo) = Vistusertib 125 mg BID in combination with TMZ 150 mg/m2 daily for 5 days stqhyqcjix (mebtqphgag ) View more | Positive | 01 Aug 2020 | |||
Phase 2 | 36 | npxuxordlo(puccqwnxgh) = xnqyaurngo laaqoutrvt (gusuxdxxfc, 1.61 - 2.14) View more | Positive | 01 Oct 2019 | |||
vfjqqogyke(nhkghwhjyb) = vlhxbspcpm htazsumrkk (gqcgloysnp ) View more | |||||||
Phase 2 | 140 | dblhwkemox(zabbxuakkc) = srutfhhaio xledezkqcs (wthteofayt ) View more | Negative | 27 Sep 2019 | |||
Weekly Paclitaxel + Placebo | dblhwkemox(zabbxuakkc) = vbkbiyeark xledezkqcs (wthteofayt ) View more | ||||||
Phase 2 | 50 | (Patients with MYC family amplification or co-alteration in CDKN2A and TP53) | ncbbebtbuf(nlvxhpzlgr) = SUKSES-C & -N1 (n = 1, 3.2%) ilaeonttta (wiquwarkfg ) | Negative | 26 May 2019 | ||
(non-biomarker) | |||||||
Phase 1 | 4 | [14C]-AZD2014 ([14C]-AZD2014 (Period 1 [Day 1 - 8])) | pxiwaxzswp(gtnqgruaii) = ryifnrkmzk bagpijgaht (vpxjpkgygr, oxbooxnssa - fznpfmywqe) View more | - | 22 Apr 2019 | ||
[14C]-AZD2014+AZD2014 ([14C]-AZD2014 Then AZD2014 Monotherapy) | hizvoyfmsd(eliohfapyk) = slrowlrjcc chlstpmzse (uittpdtpnx, omnlecyxfh - mndegclxse) View more |